Observational Study to Evaluate the Safety and Efficacy of Levemir® in Type 2 Diabetes

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Africa. The aim of this study is to assess the safety and efficacy of Levemir® treatment for insulin naive patients with type 2 diabetes under normal clinical practice conditions in Algeria.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Detemir

Criteria

Inclusion Criteria:

• Informed consent obtained before any trial-related activities

• Type 2 diabetes

• HbA1c between 7-9%

• Insulin naive

• Inadequate control with oral antidiabetics therapy as judged by investigator

Exclusion Criteria:

• Patients with type 1 diabetes

• Hypersensitivity to Levemir® or to any of the excipients

• Pregnancy, or desire of pregnancy within next 6 months

• HbA1c greater than or equal to 9%

• Known or suspected allergy to the trial product or to any of the excipients

• Subjects who are unlikely to comply with protocol